{"nctId":"NCT04513652","briefTitle":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","startDateStruct":{"date":"2020-09-03","type":"ACTUAL"},"conditions":["Anesthesia, Local"],"count":120,"armGroups":[{"label":"AG-920","type":"EXPERIMENTAL","interventionNames":["Drug: AG-920"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"AG-920","otherNames":["articaine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provide written informed consent prior to any study-related procedures being performed.\n2. Is male or a non-pregnant, non-lactating female aged 18 years or older.\n3. Willing and able to follow instructions and be present for the required study visits.\n4. Have an Early Treatment Diabetic Retinopathy Study (ETDRS) Best Correct Visual Acuity (BCVA) of 20/200 or better in each eye.\n5. Have an Intraocular Pressure (IOP) between 7 and 30 mmHg.\n6. Certified as healthy by clinical assessment.\n7. Verbal communication skills adequate to participate.\n8. Able to tolerate bilateral instillation of Over-The-Counter artificial tear product based on investigator judgement.\n\nExclusion Criteria:\n\n1. Have participated in an investigational study within the past 30 days.\n2. Have a contraindication to local anesthetics.\n3. Have known decreased corneal or conjunctival sensitivity.\n4. Have had ocular surgery in either eye within the past 90 days.\n5. Have had an intravitreal injection in either eye within 14 days.\n6. Have ocular disease requiring punctual plugs or ocular inflammation.\n7. Are currently using a systemic opioid or opiate analgesic or topical NSAID.\n8. Cannot withhold their over the counter (OTC) artificial tear lubricant products for one hour preceding or following study medication.\n9. Any condition, including alcohol or drug dependency, that would limit the subject's ability to comply with the procedures of the protocol.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes","description":"Immediately following EACH pinch test, subjects will be asked \"Was that painful\" \"Yes\" or \"NO.\"","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time in Minutes of AG-920 to Anesthetize the Eye","description":"Mean time to no pain score (onset)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.442","spread":"0.6072"},{"groupId":"OG001","value":"0.330","spread":"0.0000"}]}]}]},{"type":"SECONDARY","title":"To Evaluate How Long One Dose of AG-920 Anesthetizes the Eye","description":"Mean duration of anesthetic effect","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.833","spread":"3.8158"},{"groupId":"OG001","value":"0.267","spread":"1.4325"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"TEAEs will be summarized by treatment group using frequency and percent for each system organ class and preferred term within each system, organ and class (SOC). Summaries will be presented separately for ocular and non-ocular Adverse Events (AEs).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Change in Biomicroscopy","description":"Slit lamp biomicroscopy and external eye exam measures will be summarized at each measured time point using discrete summary statistics. Clinician examined the eyelid, conjunctiva, cornea, anterior chamber, iris, pupil and lens of the eye with the aid of a slit lamp.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Visual Acuity","description":"Visual Acuity data will be summarized at each time point using continuous and discrete summaries of Logarithmic Minimum Angle of Resolution (logMAR). Distance visual acuity was assessed using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or equivalent chart. The subject should attempt to read each letter, line by line, left to right, beginning with line 1 at the top of the chart (20/200 line).The number of letters missed is multiplied by 0.02 and added to the baseline value to determine the logMAR visual acuity. Baseline is defined as the last line for which the subject reads at least one letter. logMAR units VA = Baseline value + (n x 0.02).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0090","spread":"0.07541"},{"groupId":"OG001","value":"-0.0113","spread":"0.04862"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0110","spread":"0.05977"},{"groupId":"OG001","value":"-0.0110","spread":"0.04821"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Instillation Site Pain","Conjunctival Hyperaemia","Dysgeusia"]}}}